Table 2. Relationship between clinical characteristics and cytoreductive outcomes.
| Characteristics | Optimal debulking* |
Suboptimal debulking** |
P | |||
|---|---|---|---|---|---|---|
| n | % | n | % | |||
| FIGO stage | 0.360 | |||||
| III | 40 | 49.4 | 41 | 50.6 | ||
| IV | 3 | 33.3 | 6 | 66.7 | ||
| Grade | 0.636 | |||||
| 1 | 2 | 66.7 | 1 | 33.3 | ||
| 2 | 5 | 38.5 | 8 | 61.5 | ||
| 3 | 36 | 48.6 | 38 | 51.4 | ||
| Histopathology | 0.059 | |||||
| Serous | 32 | 55.2 | 26 | 44.8 | ||
| Non-serous | 11 | 34.4 | 21 | 65.6 | ||
| Preoperative HE4 (pmol/L) | <0.001 | |||||
| <473 | 24 | 72.7 | 9 | 27.3 | ||
| ≥473 | 19 | 33.3 | 38 | 66.7 | ||
| Preoperative CA125 (U/mL) | 0.033 | |||||
| <500 | 17 | 65.4 | 9 | 34.6 | ||
| ≥500 | 26 | 40.6 | 38 | 59.4 | ||
| Lymph node status | <0.001 | |||||
| No lymphadenectomy | 2 | 6.7 | 28 | 93.3 | ||
| Negative | 17 | 73.9 | 6 | 26.1 | ||
| Positive | 24 | 64.9 | 13 | 35.1 | ||
| Ascites [median (range)] (mL) | 0.022 | |||||
| ≤1,000 [200 (0-1,000)] | 25 | 61 | 16 | 39 | ||
| >1,000 [3,000 (1,500-8,500)] | 18 | 36.7 | 31 | 63.3 | ||
*, “optimal” was identified using the threshold of ≤1 cm residual disease; **, “suboptimal” was with residual disease >1 cm. FIGO, International Federation of Gynecology and Obstetrics; HE4, human epididymis protein 4.